Schmid Mattia, Gemperle Claudio, Rimann Nicole, Hersberger Martin
Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland; and Center for Integrative Human Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland; Children's Research Center, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland; and Center for Integrative Human Physiology, University of Zurich, CH-8057 Zurich, Switzerland
J Immunol. 2016 Apr 15;196(8):3429-37. doi: 10.4049/jimmunol.1501701. Epub 2016 Mar 11.
Resolvin D1 (RvD1) was shown to be a potent anti-inflammatory and proresolution lipid mediator in several animal models of inflammation, but its mechanism of action in humans is not clear. We show that the RvD1 receptor GPR32 is present on resting, proinflammatory M(LPS) and alternatively activated primary human M(IL-4) macrophages, whereas TGF-β and IL-6 reduce its membrane expression. Accordingly, stimulation of resting primary human macrophages with 10 nM RvD1 for 48 h maximally reduced the secretion of the proinflammatory cytokines IL-1β and IL-8; abolished chemotaxis to several chemoattractants like chemerin, fMLF, and MCP-1; and doubled the phagocytic activity of these macrophages toward microbial particles. In contrast, these functional changes were not accompanied by surface expression of markers specific for alternatively activated M(IL-4) macrophages. Similar proresolution effects of RvD1 were observed when proinflammatory M(LPS) macrophages were treated with RvD1. In addition, we show that these RvD1-mediated effects are GPR32 dependent because reduction of GPR32 expression by small interfering RNA, TGF-β, and IL-6 treatment ablated these proresolution effects in primary human macrophages. Taken together, our results indicate that in humans RvD1 triggers GPR32 to polarize and repolarize macrophages toward a proresolution phenotype, supporting the role of this mediator in the resolution of inflammation in humans.
在多种炎症动物模型中,消退素D1(RvD1)被证明是一种强效的抗炎和促消退脂质介质,但其在人类中的作用机制尚不清楚。我们发现,RvD1受体GPR32存在于静息的促炎M(LPS)巨噬细胞和经诱导活化的原代人M(IL-4)巨噬细胞上,而转化生长因子-β(TGF-β)和白细胞介素-6(IL-6)会降低其膜表达。相应地,用10 nM RvD1刺激静息的原代人巨噬细胞48小时,可最大程度地减少促炎细胞因子白细胞介素-1β(IL-1β)和白细胞介素-8(IL-8)的分泌;消除对多种趋化因子(如chemerin、fMLF和单核细胞趋化蛋白-1(MCP-1))的趋化作用;并使这些巨噬细胞对微生物颗粒的吞噬活性提高一倍。相比之下,这些功能变化并未伴随经诱导活化的M(IL-4)巨噬细胞特异性标志物的表面表达。用RvD1处理促炎M(LPS)巨噬细胞时,也观察到了类似的RvD1促消退作用。此外,我们发现这些RvD1介导的作用依赖于GPR32,因为用小干扰RNA、TGF-β和IL-6处理降低GPR32表达后,原代人巨噬细胞中的这些促消退作用消失。综上所述,我们的结果表明,在人类中,RvD1触发GPR32使巨噬细胞极化并重新极化至促消退表型,支持了这种介质在人类炎症消退中的作用。